Novo Nordisk NVO, +1.48% NOVO.B, +1.93% said Thursday it has entered research collaboration agreements with Omega Therapeutics Inc. OMGA, -8.08% and Cellarity on new treatments for obesity management. The Danish developer of weight-loss drugs Ozempic and Wegovy said the Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller that aims to enhance metabolic activity. The Cellarity collaboration aims to discover biological drivers of metabolic dysfunction-asso ...

Novo Nordisk (NVO) closed the most recent trading day at $103.62, moving +1.48% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.8%. On the other hand, the Dow registered a loss of 0.76%, and the technology-centric Nasdaq decreased by 1.18%.Coming into today, shares of the drugmaker had gained 2.49% in the past month. In that same time, the Medical sector gained 5.8%, while the S&P 500 gained 3.4%.The investment community will be paying close attention to the ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event November 11, 2023 6:00 PM ET Company Participants Daniel Bohsen - Head of Investor Relations Martin Holst Lange - Executive Vice President, Development Robin Evers - Senior Vice President of Medical Affairs, Regulatory and Safety Conference Call Participants Richard Vosser - JPMorgan Chase & Co Emily Field - Barclays Michael Novod - Nordea Pete Verdult - Citi Seamus Fernandez - Guggenheim Securities Martin Parkhøi - SEB Pete Welford - Jefferies Michael ...

Novo Nordisk A/S (NVO) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Daniel Bohsen - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President, Commercial Strategy and Corporate Affairs Doug Langa - Executive Vice President, North America Operations Martin Holst Lange - Executive Vice President, Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Ca ...

1 Investor presentation First six months of 2023 RAFAEL VALVERDE Rafael lives with obesity Mexico Novo Nordisk –a focused healthcare company Investor presentation First six months of 2023 2 Novo Nordisk® Investor presentation First six months of 2023 Agenda Progress on Strategic Aspirations 2025 Commercial execution Agenda Innovation and therapeutic focus Financials 3 Novo Nordisk® Investor presentation First six months of 2023 Forward-looking statements Novo Nordisk's reports filed with or furnished to the ...

Novo Nordisk A/S (NVO) Q2 2023 Earnings Conference Call August 10, 2023 7:00 AM ET Company Participants Daniel Bohsen - CVP & Head, IR Lars Jorgensen - President & CEO Camilla Sylvest - EVP, Commercial Strategy & Corporate Affairs Douglas Langa - EVP, North America Operations Martin Lange - EVP, Development Karsten Knudsen - EVP & CFO Conference Call Participants Martin Parkhoi - SEB Richard Parkes - BNP Paribas Exane Emily Field - Barclays Bank Peter Verdult - Citigroup Harry Sephton - Crédit Suisse Peter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 3, 2023 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 6-K _________________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 1, 2023 _________________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) _________________________ Novo Allé DK-2880 Bagsværd Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or w ...